nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—endothelium—atherosclerosis	0.043	0.292	CbGeAlD
Plerixafor—CXCR4—blood vessel—atherosclerosis	0.0397	0.269	CbGeAlD
Plerixafor—CXCR4—connective tissue—atherosclerosis	0.0204	0.138	CbGeAlD
Plerixafor—CXCR4—cardiovascular system—atherosclerosis	0.0177	0.12	CbGeAlD
Plerixafor—CXCR4—adipose tissue—atherosclerosis	0.0156	0.106	CbGeAlD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCL4—atherosclerosis	0.0126	0.0312	CbGpPWpGaD
Plerixafor—CXCR4—liver—atherosclerosis	0.011	0.0743	CbGeAlD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CX3CR1—atherosclerosis	0.0108	0.0266	CbGpPWpGaD
Plerixafor—Upset stomach—Lovastatin—atherosclerosis	0.0106	0.0238	CcSEcCtD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CX3CL1—atherosclerosis	0.0106	0.0261	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—PLG—atherosclerosis	0.0101	0.025	CbGpPWpGaD
Plerixafor—Upset stomach—Simvastatin—atherosclerosis	0.00995	0.0222	CcSEcCtD
Plerixafor—CXCR4—S1P3 pathway—PDGFB—atherosclerosis	0.00912	0.0225	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—CCL5—atherosclerosis	0.00874	0.0216	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—CX3CR1—atherosclerosis	0.00864	0.0213	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCL3—atherosclerosis	0.00863	0.0213	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCR2—atherosclerosis	0.00781	0.0193	CbGpPWpGaD
Plerixafor—Musculoskeletal pain—Lovastatin—atherosclerosis	0.00705	0.0158	CcSEcCtD
Plerixafor—Inflammation—Ezetimibe—atherosclerosis	0.00705	0.0158	CcSEcCtD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—F2—atherosclerosis	0.00675	0.0167	CbGpPWpGaD
Plerixafor—Inflammation—Simvastatin—atherosclerosis	0.00672	0.015	CcSEcCtD
Plerixafor—CXCR4—Peptide GPCRs—CCR2—atherosclerosis	0.00625	0.0154	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—EDNRA—atherosclerosis	0.00625	0.0154	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—IGF2—atherosclerosis	0.00616	0.0152	CbGpPWpGaD
Plerixafor—Musculoskeletal pain—Pravastatin—atherosclerosis	0.00597	0.0133	CcSEcCtD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCL5—atherosclerosis	0.00558	0.0138	CbGpPWpGaD
Plerixafor—Swelling—Simvastatin—atherosclerosis	0.00536	0.012	CcSEcCtD
Plerixafor—CXCR4—Peptide GPCRs—AGTR1—atherosclerosis	0.00531	0.0131	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—HMOX1—atherosclerosis	0.00523	0.0129	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—HRH1—atherosclerosis	0.00515	0.0127	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—EDN1—atherosclerosis	0.00493	0.0122	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCL4—atherosclerosis	0.00476	0.0117	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—atherosclerosis	0.00471	0.0116	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—MAPK3—atherosclerosis	0.00445	0.011	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.00441	0.0109	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—atherosclerosis	0.0043	0.0106	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—UTS2—atherosclerosis	0.00424	0.0105	CbGpPWpGaD
Plerixafor—Abdominal discomfort—Lovastatin—atherosclerosis	0.00419	0.00937	CcSEcCtD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—INS—atherosclerosis	0.00409	0.0101	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CX3CR1—atherosclerosis	0.00406	0.01	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—LEP—atherosclerosis	0.00401	0.0099	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CX3CL1—atherosclerosis	0.00399	0.00983	CbGpPWpGaD
Plerixafor—Orthostatic hypotension—Niacin—atherosclerosis	0.00397	0.00887	CcSEcCtD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—IGF1—atherosclerosis	0.00395	0.00975	CbGpPWpGaD
Plerixafor—Abdominal discomfort—Simvastatin—atherosclerosis	0.00392	0.00876	CcSEcCtD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCL2—atherosclerosis	0.00385	0.00949	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL1B—atherosclerosis	0.00382	0.00942	CbGpPWpGaD
Plerixafor—Abdominal distension—Niacin—atherosclerosis	0.00378	0.00845	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—NOS2—atherosclerosis	0.00374	0.00923	CbGpPWpGaD
Plerixafor—Abdominal distension—Pravastatin—atherosclerosis	0.00372	0.00832	CcSEcCtD
Plerixafor—Mental disorder—Rosuvastatin—atherosclerosis	0.00362	0.00809	CcSEcCtD
Plerixafor—Flatulence—Rosuvastatin—atherosclerosis	0.00354	0.00792	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CASR—atherosclerosis	0.00343	0.00846	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00337	0.00754	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—HRH1—atherosclerosis	0.00336	0.00829	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCL3—atherosclerosis	0.00325	0.00802	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.00319	0.00787	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CNR2—atherosclerosis	0.00319	0.00786	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CX3CR1—atherosclerosis	0.00318	0.00785	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—SERPINE1—atherosclerosis	0.00315	0.00777	CbGpPWpGaD
Plerixafor—Immune system disorder—Ezetimibe—atherosclerosis	0.0031	0.00693	CcSEcCtD
Plerixafor—Arthralgia—Rosuvastatin—atherosclerosis	0.00306	0.00684	CcSEcCtD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CXCL8—atherosclerosis	0.00304	0.0075	CbGpPWpGaD
Plerixafor—Haemoglobin—Niacin—atherosclerosis	0.00302	0.00675	CcSEcCtD
Plerixafor—Mental disorder—Ezetimibe—atherosclerosis	0.00301	0.00672	CcSEcCtD
Plerixafor—Haemorrhage—Niacin—atherosclerosis	0.00301	0.00672	CcSEcCtD
Plerixafor—CXCR4—S1P3 pathway—AKT1—atherosclerosis	0.003	0.00741	CbGpPWpGaD
Plerixafor—Flatulence—Lovastatin—atherosclerosis	0.003	0.00671	CcSEcCtD
Plerixafor—Erythema—Ezetimibe—atherosclerosis	0.00299	0.00668	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CG—atherosclerosis	0.00299	0.00737	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CNR2—atherosclerosis	0.00296	0.0073	CbGpPWpGaD
Plerixafor—Flatulence—Ezetimibe—atherosclerosis	0.00294	0.00658	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—EDNRA—atherosclerosis	0.00294	0.00725	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCR2—atherosclerosis	0.00294	0.00725	CbGpPWpGaD
Plerixafor—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00288	0.00643	CcSEcCtD
Plerixafor—Mental disorder—Simvastatin—atherosclerosis	0.00287	0.00641	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—GHRL—atherosclerosis	0.00286	0.00706	CbGpPWpGaD
Plerixafor—Erythema—Simvastatin—atherosclerosis	0.00285	0.00637	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.00284	0.00701	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Lovastatin—atherosclerosis	0.00283	0.00632	CcSEcCtD
Plerixafor—Flatulence—Simvastatin—atherosclerosis	0.00281	0.00628	CcSEcCtD
Plerixafor—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00277	0.0062	CcSEcCtD
Plerixafor—Malaise—Lovastatin—atherosclerosis	0.00275	0.00614	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.00273	0.00673	CbGpPWpGaD
Plerixafor—Malaise—Ezetimibe—atherosclerosis	0.00269	0.00602	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00267	0.00598	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.00267	0.0066	CbGpPWpGaD
Plerixafor—Insomnia—Rosuvastatin—atherosclerosis	0.00265	0.00593	CcSEcCtD
Plerixafor—Ill-defined disorder—Simvastatin—atherosclerosis	0.00264	0.00591	CcSEcCtD
Plerixafor—Paraesthesia—Rosuvastatin—atherosclerosis	0.00263	0.00589	CcSEcCtD
Plerixafor—Erythema—Niacin—atherosclerosis	0.00262	0.00585	CcSEcCtD
Plerixafor—Arthralgia—Lovastatin—atherosclerosis	0.00259	0.0058	CcSEcCtD
Plerixafor—Dyspepsia—Rosuvastatin—atherosclerosis	0.00258	0.00577	CcSEcCtD
Plerixafor—Flatulence—Niacin—atherosclerosis	0.00258	0.00576	CcSEcCtD
Plerixafor—Malaise—Simvastatin—atherosclerosis	0.00257	0.00574	CcSEcCtD
Plerixafor—Discomfort—Lovastatin—atherosclerosis	0.00256	0.00573	CcSEcCtD
Plerixafor—Arthralgia—Ezetimibe—atherosclerosis	0.00254	0.00569	CcSEcCtD
Plerixafor—Flatulence—Pravastatin—atherosclerosis	0.00254	0.00568	CcSEcCtD
Plerixafor—Dry mouth—Lovastatin—atherosclerosis	0.00254	0.00567	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.00253	0.00625	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00253	0.00565	CcSEcCtD
Plerixafor—Discomfort—Ezetimibe—atherosclerosis	0.00251	0.00562	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—KNG1—atherosclerosis	0.00251	0.0062	CbGpPWpGaD
Plerixafor—Pain—Rosuvastatin—atherosclerosis	0.00251	0.00561	CcSEcCtD
Plerixafor—Constipation—Rosuvastatin—atherosclerosis	0.00251	0.00561	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—AGTR1—atherosclerosis	0.0025	0.00616	CbGpPWpGaD
Plerixafor—Dry mouth—Ezetimibe—atherosclerosis	0.00249	0.00556	CcSEcCtD
Plerixafor—Anaphylactic shock—Lovastatin—atherosclerosis	0.00249	0.00556	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CCR2—atherosclerosis	0.00248	0.00612	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00244	0.00545	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CCL4—atherosclerosis	0.00243	0.00599	CbGpPWpGaD
Plerixafor—Arthralgia—Simvastatin—atherosclerosis	0.00243	0.00542	CcSEcCtD
Plerixafor—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00242	0.0054	CcSEcCtD
Plerixafor—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.0024	0.00536	CcSEcCtD
Plerixafor—Discomfort—Simvastatin—atherosclerosis	0.0024	0.00536	CcSEcCtD
Plerixafor—Nervous system disorder—Ezetimibe—atherosclerosis	0.00239	0.00535	CcSEcCtD
Plerixafor—Ill-defined disorder—Pravastatin—atherosclerosis	0.00239	0.00534	CcSEcCtD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—TGFB1—atherosclerosis	0.00237	0.00585	CbGpPWpGaD
Plerixafor—Skin disorder—Ezetimibe—atherosclerosis	0.00237	0.0053	CcSEcCtD
Plerixafor—Syncope—Niacin—atherosclerosis	0.00235	0.00525	CcSEcCtD
Plerixafor—Urticaria—Rosuvastatin—atherosclerosis	0.00233	0.00521	CcSEcCtD
Plerixafor—Anaphylactic shock—Simvastatin—atherosclerosis	0.00233	0.0052	CcSEcCtD
Plerixafor—Malaise—Pravastatin—atherosclerosis	0.00232	0.00519	CcSEcCtD
Plerixafor—Abdominal pain—Rosuvastatin—atherosclerosis	0.00232	0.00518	CcSEcCtD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—EDNRA—atherosclerosis	0.0023	0.00568	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	0.0023	0.00568	CbGpPWpGaD
Plerixafor—Loss of consciousness—Niacin—atherosclerosis	0.0023	0.00514	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00227	0.00506	CcSEcCtD
Plerixafor—Insomnia—Lovastatin—atherosclerosis	0.00225	0.00503	CcSEcCtD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—atherosclerosis	0.00224	0.00552	CbGpPWpGaD
Plerixafor—Paraesthesia—Lovastatin—atherosclerosis	0.00223	0.00499	CcSEcCtD
Plerixafor—Arthralgia—Niacin—atherosclerosis	0.00223	0.00498	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00222	0.00497	CcSEcCtD
Plerixafor—Dyspnoea—Lovastatin—atherosclerosis	0.00222	0.00496	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00221	0.00495	CcSEcCtD
Plerixafor—Insomnia—Ezetimibe—atherosclerosis	0.00221	0.00493	CcSEcCtD
Plerixafor—Arthralgia—Pravastatin—atherosclerosis	0.00219	0.0049	CcSEcCtD
Plerixafor—Paraesthesia—Ezetimibe—atherosclerosis	0.00219	0.0049	CcSEcCtD
Plerixafor—Dyspepsia—Lovastatin—atherosclerosis	0.00219	0.00489	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.00218	0.00538	CbGpPWpGaD
Plerixafor—Dry mouth—Niacin—atherosclerosis	0.00218	0.00487	CcSEcCtD
Plerixafor—Dyspnoea—Ezetimibe—atherosclerosis	0.00217	0.00486	CcSEcCtD
Plerixafor—Discomfort—Pravastatin—atherosclerosis	0.00217	0.00484	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—atherosclerosis	0.00217	0.00534	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—UTS2—atherosclerosis	0.00216	0.00534	CbGpPWpGaD
Plerixafor—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00216	0.00483	CcSEcCtD
Plerixafor—Dyspepsia—Ezetimibe—atherosclerosis	0.00215	0.0048	CcSEcCtD
Plerixafor—Fatigue—Lovastatin—atherosclerosis	0.00214	0.00479	CcSEcCtD
Plerixafor—Anaphylactic shock—Niacin—atherosclerosis	0.00214	0.00477	CcSEcCtD
Plerixafor—Constipation—Lovastatin—atherosclerosis	0.00213	0.00475	CcSEcCtD
Plerixafor—Pain—Lovastatin—atherosclerosis	0.00213	0.00475	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—KNG1—atherosclerosis	0.00212	0.00523	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00212	0.00474	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—EDN1—atherosclerosis	0.00212	0.00523	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00211	0.00471	CcSEcCtD
Plerixafor—Asthenia—Rosuvastatin—atherosclerosis	0.00211	0.00471	CcSEcCtD
Plerixafor—Insomnia—Simvastatin—atherosclerosis	0.0021	0.0047	CcSEcCtD
Plerixafor—Anaphylactic shock—Pravastatin—atherosclerosis	0.0021	0.0047	CcSEcCtD
Plerixafor—Fatigue—Ezetimibe—atherosclerosis	0.0021	0.0047	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCL5—atherosclerosis	0.0021	0.00518	CbGpPWpGaD
Plerixafor—Shock—Niacin—atherosclerosis	0.0021	0.0047	CcSEcCtD
Plerixafor—Paraesthesia—Simvastatin—atherosclerosis	0.00209	0.00467	CcSEcCtD
Plerixafor—Pain—Ezetimibe—atherosclerosis	0.00209	0.00466	CcSEcCtD
Plerixafor—Constipation—Ezetimibe—atherosclerosis	0.00209	0.00466	CcSEcCtD
Plerixafor—Pruritus—Rosuvastatin—atherosclerosis	0.00208	0.00464	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CX3CR1—atherosclerosis	0.00208	0.00512	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CASR—atherosclerosis	0.00208	0.00512	CbGpPWpGaD
Plerixafor—Skin disorder—Niacin—atherosclerosis	0.00207	0.00464	CcSEcCtD
Plerixafor—Dyspnoea—Simvastatin—atherosclerosis	0.00207	0.00464	CcSEcCtD
Plerixafor—Hyperhidrosis—Niacin—atherosclerosis	0.00206	0.00462	CcSEcCtD
Plerixafor—Feeling abnormal—Lovastatin—atherosclerosis	0.00205	0.00458	CcSEcCtD
Plerixafor—Dyspepsia—Simvastatin—atherosclerosis	0.00205	0.00458	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CX3CL1—atherosclerosis	0.00204	0.00502	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00203	0.00455	CcSEcCtD
Plerixafor—Hyperhidrosis—Pravastatin—atherosclerosis	0.00203	0.00454	CcSEcCtD
Plerixafor—Feeling abnormal—Ezetimibe—atherosclerosis	0.00201	0.00449	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00201	0.00449	CcSEcCtD
Plerixafor—Diarrhoea—Rosuvastatin—atherosclerosis	0.00201	0.00449	CcSEcCtD
Plerixafor—Fatigue—Simvastatin—atherosclerosis	0.00201	0.00448	CcSEcCtD
Plerixafor—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00199	0.00446	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—atherosclerosis	0.00199	0.00491	CbGpPWpGaD
Plerixafor—Pain—Simvastatin—atherosclerosis	0.00199	0.00445	CcSEcCtD
Plerixafor—Constipation—Simvastatin—atherosclerosis	0.00199	0.00445	CcSEcCtD
Plerixafor—Urticaria—Lovastatin—atherosclerosis	0.00198	0.00442	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.00197	0.00486	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.00197	0.00486	CbGpPWpGaD
Plerixafor—Abdominal pain—Lovastatin—atherosclerosis	0.00197	0.00439	CcSEcCtD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.00196	0.00483	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00195	0.00435	CcSEcCtD
Plerixafor—Dizziness—Rosuvastatin—atherosclerosis	0.00194	0.00434	CcSEcCtD
Plerixafor—Urticaria—Ezetimibe—atherosclerosis	0.00194	0.00433	CcSEcCtD
Plerixafor—Insomnia—Niacin—atherosclerosis	0.00193	0.00432	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CNR2—atherosclerosis	0.00193	0.00476	CbGpPWpGaD
Plerixafor—Abdominal pain—Ezetimibe—atherosclerosis	0.00193	0.00431	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.00192	0.00474	CbGpPWpGaD
Plerixafor—Paraesthesia—Niacin—atherosclerosis	0.00192	0.00429	CcSEcCtD
Plerixafor—Feeling abnormal—Simvastatin—atherosclerosis	0.00192	0.00428	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00192	0.00428	CcSEcCtD
Plerixafor—Dyspnoea—Niacin—atherosclerosis	0.0019	0.00426	CcSEcCtD
Plerixafor—Gastrointestinal pain—Simvastatin—atherosclerosis	0.0019	0.00425	CcSEcCtD
Plerixafor—Insomnia—Pravastatin—atherosclerosis	0.0019	0.00425	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—HRH1—atherosclerosis	0.0019	0.00468	CbGpPWpGaD
Plerixafor—Paraesthesia—Pravastatin—atherosclerosis	0.00189	0.00422	CcSEcCtD
Plerixafor—Dyspepsia—Niacin—atherosclerosis	0.00188	0.0042	CcSEcCtD
Plerixafor—Dyspnoea—Pravastatin—atherosclerosis	0.00187	0.00419	CcSEcCtD
Plerixafor—Dyspepsia—Pravastatin—atherosclerosis	0.00185	0.00414	CcSEcCtD
Plerixafor—Rash—Rosuvastatin—atherosclerosis	0.00185	0.00414	CcSEcCtD
Plerixafor—Dermatitis—Rosuvastatin—atherosclerosis	0.00185	0.00413	CcSEcCtD
Plerixafor—Urticaria—Simvastatin—atherosclerosis	0.00185	0.00413	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Niacin—atherosclerosis	0.00184	0.00412	CcSEcCtD
Plerixafor—Abdominal pain—Simvastatin—atherosclerosis	0.00184	0.00411	CcSEcCtD
Plerixafor—Headache—Rosuvastatin—atherosclerosis	0.00184	0.00411	CcSEcCtD
Plerixafor—Hypersensitivity—Lovastatin—atherosclerosis	0.00183	0.0041	CcSEcCtD
Plerixafor—Pain—Niacin—atherosclerosis	0.00183	0.00408	CcSEcCtD
Plerixafor—Fatigue—Pravastatin—atherosclerosis	0.00181	0.00405	CcSEcCtD
Plerixafor—Pain—Pravastatin—atherosclerosis	0.0018	0.00402	CcSEcCtD
Plerixafor—Constipation—Pravastatin—atherosclerosis	0.0018	0.00402	CcSEcCtD
Plerixafor—Hypersensitivity—Ezetimibe—atherosclerosis	0.0018	0.00402	CcSEcCtD
Plerixafor—Asthenia—Lovastatin—atherosclerosis	0.00178	0.00399	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CCL5—atherosclerosis	0.00177	0.00437	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—atherosclerosis	0.00177	0.00436	CbGpPWpGaD
Plerixafor—Pruritus—Lovastatin—atherosclerosis	0.00176	0.00393	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—AGT—atherosclerosis	0.00176	0.00434	CbGpPWpGaD
Plerixafor—Asthenia—Ezetimibe—atherosclerosis	0.00175	0.00391	CcSEcCtD
Plerixafor—Gastrointestinal pain—Niacin—atherosclerosis	0.00175	0.0039	CcSEcCtD
Plerixafor—Nausea—Rosuvastatin—atherosclerosis	0.00174	0.0039	CcSEcCtD
Plerixafor—Feeling abnormal—Pravastatin—atherosclerosis	0.00173	0.00387	CcSEcCtD
Plerixafor—Pruritus—Ezetimibe—atherosclerosis	0.00173	0.00386	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—HRH1—atherosclerosis	0.00172	0.00425	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00172	0.00384	CcSEcCtD
Plerixafor—Hypersensitivity—Simvastatin—atherosclerosis	0.00171	0.00383	CcSEcCtD
Plerixafor—Diarrhoea—Lovastatin—atherosclerosis	0.0017	0.0038	CcSEcCtD
Plerixafor—Urticaria—Niacin—atherosclerosis	0.0017	0.00379	CcSEcCtD
Plerixafor—Abdominal pain—Niacin—atherosclerosis	0.00169	0.00377	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.00169	0.00416	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.00168	0.00413	CbGpPWpGaD
Plerixafor—Urticaria—Pravastatin—atherosclerosis	0.00167	0.00373	CcSEcCtD
Plerixafor—Asthenia—Simvastatin—atherosclerosis	0.00167	0.00373	CcSEcCtD
Plerixafor—Diarrhoea—Ezetimibe—atherosclerosis	0.00167	0.00373	CcSEcCtD
Plerixafor—Abdominal pain—Pravastatin—atherosclerosis	0.00166	0.00372	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CCL3—atherosclerosis	0.00166	0.00409	CbGpPWpGaD
Plerixafor—Pruritus—Simvastatin—atherosclerosis	0.00165	0.00368	CcSEcCtD
Plerixafor—Dizziness—Lovastatin—atherosclerosis	0.00164	0.00368	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—F2—atherosclerosis	0.00162	0.00401	CbGpPWpGaD
Plerixafor—Dizziness—Ezetimibe—atherosclerosis	0.00161	0.00361	CcSEcCtD
Plerixafor—Diarrhoea—Simvastatin—atherosclerosis	0.00159	0.00356	CcSEcCtD
Plerixafor—Vomiting—Lovastatin—atherosclerosis	0.00158	0.00353	CcSEcCtD
Plerixafor—Hypersensitivity—Niacin—atherosclerosis	0.00157	0.00352	CcSEcCtD
Plerixafor—Rash—Lovastatin—atherosclerosis	0.00157	0.0035	CcSEcCtD
Plerixafor—Dermatitis—Lovastatin—atherosclerosis	0.00157	0.0035	CcSEcCtD
Plerixafor—Headache—Lovastatin—atherosclerosis	0.00156	0.00348	CcSEcCtD
Plerixafor—Vomiting—Ezetimibe—atherosclerosis	0.00155	0.00347	CcSEcCtD
Plerixafor—Hypersensitivity—Pravastatin—atherosclerosis	0.00155	0.00346	CcSEcCtD
Plerixafor—Dizziness—Simvastatin—atherosclerosis	0.00154	0.00344	CcSEcCtD
Plerixafor—Rash—Ezetimibe—atherosclerosis	0.00154	0.00344	CcSEcCtD
Plerixafor—Dermatitis—Ezetimibe—atherosclerosis	0.00154	0.00343	CcSEcCtD
Plerixafor—Asthenia—Niacin—atherosclerosis	0.00153	0.00343	CcSEcCtD
Plerixafor—Headache—Ezetimibe—atherosclerosis	0.00153	0.00342	CcSEcCtD
Plerixafor—Pruritus—Niacin—atherosclerosis	0.00151	0.00338	CcSEcCtD
Plerixafor—Asthenia—Pravastatin—atherosclerosis	0.00151	0.00337	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—EDNRA—atherosclerosis	0.0015	0.0037	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCR2—atherosclerosis	0.0015	0.0037	CbGpPWpGaD
Plerixafor—Pruritus—Pravastatin—atherosclerosis	0.00149	0.00333	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—AGT—atherosclerosis	0.00148	0.00366	CbGpPWpGaD
Plerixafor—Vomiting—Simvastatin—atherosclerosis	0.00148	0.00331	CcSEcCtD
Plerixafor—Nausea—Lovastatin—atherosclerosis	0.00148	0.0033	CcSEcCtD
Plerixafor—Rash—Simvastatin—atherosclerosis	0.00147	0.00328	CcSEcCtD
Plerixafor—Dermatitis—Simvastatin—atherosclerosis	0.00147	0.00328	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—GHRL—atherosclerosis	0.00146	0.00361	CbGpPWpGaD
Plerixafor—Diarrhoea—Niacin—atherosclerosis	0.00146	0.00327	CcSEcCtD
Plerixafor—Headache—Simvastatin—atherosclerosis	0.00146	0.00326	CcSEcCtD
Plerixafor—Nausea—Ezetimibe—atherosclerosis	0.00145	0.00324	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCL2—atherosclerosis	0.00145	0.00357	CbGpPWpGaD
Plerixafor—Diarrhoea—Pravastatin—atherosclerosis	0.00144	0.00322	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.00142	0.0035	CbGpPWpGaD
Plerixafor—Dizziness—Niacin—atherosclerosis	0.00141	0.00316	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.00141	0.00348	CbGpPWpGaD
Plerixafor—Dizziness—Pravastatin—atherosclerosis	0.00139	0.00311	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—atherosclerosis	0.00138	0.00341	CbGpPWpGaD
Plerixafor—Nausea—Simvastatin—atherosclerosis	0.00138	0.00309	CcSEcCtD
Plerixafor—Vomiting—Niacin—atherosclerosis	0.00136	0.00304	CcSEcCtD
Plerixafor—Rash—Niacin—atherosclerosis	0.00135	0.00301	CcSEcCtD
Plerixafor—Dermatitis—Niacin—atherosclerosis	0.00135	0.00301	CcSEcCtD
Plerixafor—Headache—Niacin—atherosclerosis	0.00134	0.00299	CcSEcCtD
Plerixafor—Vomiting—Pravastatin—atherosclerosis	0.00134	0.00299	CcSEcCtD
Plerixafor—Rash—Pravastatin—atherosclerosis	0.00133	0.00296	CcSEcCtD
Plerixafor—Dermatitis—Pravastatin—atherosclerosis	0.00132	0.00296	CcSEcCtD
Plerixafor—Headache—Pravastatin—atherosclerosis	0.00132	0.00294	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—KNG1—atherosclerosis	0.00128	0.00317	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—AGTR1—atherosclerosis	0.00128	0.00315	CbGpPWpGaD
Plerixafor—Nausea—Niacin—atherosclerosis	0.00127	0.00284	CcSEcCtD
Plerixafor—Nausea—Pravastatin—atherosclerosis	0.00125	0.00279	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CCL4—atherosclerosis	0.00125	0.00308	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—UTS2—atherosclerosis	0.00122	0.00302	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.00118	0.00291	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CASR—atherosclerosis	0.00117	0.00289	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—atherosclerosis	0.00114	0.00282	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOA4—atherosclerosis	0.00114	0.00282	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—atherosclerosis	0.00114	0.00281	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—UTS2—atherosclerosis	0.00111	0.00274	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CNR2—atherosclerosis	0.00109	0.00269	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.00109	0.00269	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—EDN1—atherosclerosis	0.00108	0.00267	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCL5—atherosclerosis	0.00107	0.00265	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CX3CR1—atherosclerosis	0.00107	0.00263	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CASR—atherosclerosis	0.00107	0.00263	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CX3CL1—atherosclerosis	0.00104	0.00258	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRH1—atherosclerosis	0.00102	0.00251	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CNR2—atherosclerosis	0.00099	0.00244	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOA2—atherosclerosis	0.000982	0.00242	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000971	0.0024	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—atherosclerosis	0.000966	0.00238	CbGpPWpGaD
Plerixafor—CXCR4—Disease—BGN—atherosclerosis	0.000908	0.00224	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—AGT—atherosclerosis	0.000898	0.00222	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCL3—atherosclerosis	0.000852	0.0021	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CCR2—atherosclerosis	0.000848	0.00209	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—EDNRA—atherosclerosis	0.000848	0.00209	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—F2—atherosclerosis	0.00083	0.00205	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GHRL—atherosclerosis	0.000826	0.00204	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOA4—atherosclerosis	0.000799	0.00197	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CST3—atherosclerosis	0.000791	0.00195	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EDNRA—atherosclerosis	0.00077	0.0019	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCR2—atherosclerosis	0.00077	0.0019	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000768	0.00189	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GHRL—atherosclerosis	0.00075	0.00185	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NAMPT—atherosclerosis	0.000749	0.00185	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOC3—atherosclerosis	0.00074	0.00183	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCL2—atherosclerosis	0.000739	0.00182	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL4—atherosclerosis	0.000736	0.00182	CbGpPWpGaD
Plerixafor—CXCR4—Disease—LDLR—atherosclerosis	0.000735	0.00181	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—KNG1—atherosclerosis	0.000725	0.00179	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AGTR1—atherosclerosis	0.000721	0.00178	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HSPA1B—atherosclerosis	0.00071	0.00175	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOA2—atherosclerosis	0.000688	0.0017	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NCF1—atherosclerosis	0.000688	0.0017	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KNG1—atherosclerosis	0.000659	0.00163	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—UTS2—atherosclerosis	0.000656	0.00162	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AGTR1—atherosclerosis	0.000655	0.00162	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CYBA—atherosclerosis	0.000647	0.0016	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PARP1—atherosclerosis	0.000633	0.00156	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CX3CR1—atherosclerosis	0.000629	0.00155	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASR—atherosclerosis	0.000629	0.00155	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CX3CL1—atherosclerosis	0.000617	0.00152	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—EDN1—atherosclerosis	0.000611	0.00151	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CCL5—atherosclerosis	0.000607	0.0015	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CNR2—atherosclerosis	0.000585	0.00144	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—atherosclerosis	0.000585	0.00144	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MMP3—atherosclerosis	0.000584	0.00144	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PRKCG—atherosclerosis	0.000577	0.00142	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EDN1—atherosclerosis	0.000555	0.00137	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCL5—atherosclerosis	0.000551	0.00136	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PRKCG—atherosclerosis	0.000524	0.00129	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VWF—atherosclerosis	0.000521	0.00129	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOC3—atherosclerosis	0.000518	0.00128	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LDLR—atherosclerosis	0.000515	0.00127	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AGT—atherosclerosis	0.000507	0.00125	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL3—atherosclerosis	0.000503	0.00124	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NCF1—atherosclerosis	0.000482	0.00119	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOB—atherosclerosis	0.000476	0.00117	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—F2—atherosclerosis	0.000469	0.00116	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AGT—atherosclerosis	0.000461	0.00114	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EDNRA—atherosclerosis	0.000455	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCR2—atherosclerosis	0.000455	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—Disease—LPL—atherosclerosis	0.000454	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CYBA—atherosclerosis	0.000453	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000449	0.00111	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PLAT—atherosclerosis	0.000443	0.00109	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PARP1—atherosclerosis	0.000443	0.00109	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GHRL—atherosclerosis	0.000443	0.00109	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PRKCG—atherosclerosis	0.000442	0.00109	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—F2—atherosclerosis	0.000426	0.00105	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTHFR—atherosclerosis	0.000409	0.00101	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—atherosclerosis	0.000407	0.00101	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PDGFB—atherosclerosis	0.000398	0.000982	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KNG1—atherosclerosis	0.000389	0.00096	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AGTR1—atherosclerosis	0.000387	0.000954	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOE—atherosclerosis	0.000381	0.00094	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCL2—atherosclerosis	0.000379	0.000936	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CAV1—atherosclerosis	0.000377	0.000931	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PLG—atherosclerosis	0.000377	0.00093	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOA1—atherosclerosis	0.000376	0.000929	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SOCS3—atherosclerosis	0.000357	0.000881	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOS2—atherosclerosis	0.000355	0.000876	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP3—atherosclerosis	0.000345	0.000851	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF2—atherosclerosis	0.000343	0.000847	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOB—atherosclerosis	0.000333	0.000822	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—atherosclerosis	0.00033	0.000815	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EDN1—atherosclerosis	0.000328	0.000809	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL5—atherosclerosis	0.000325	0.000803	CbGpPWpGaD
Plerixafor—CXCR4—Disease—INS—atherosclerosis	0.000325	0.000803	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LPL—atherosclerosis	0.000318	0.000785	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PRKCG—atherosclerosis	0.000309	0.000763	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SPP1—atherosclerosis	0.000301	0.000744	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—atherosclerosis	0.0003	0.00074	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SERPINE1—atherosclerosis	0.000299	0.000737	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOS3—atherosclerosis	0.000285	0.000704	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDGFB—atherosclerosis	0.000279	0.000688	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AGT—atherosclerosis	0.000272	0.000672	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LEP—atherosclerosis	0.000267	0.000658	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOE—atherosclerosis	0.000267	0.000658	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CAV1—atherosclerosis	0.000264	0.000652	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOA1—atherosclerosis	0.000264	0.000651	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—atherosclerosis	0.000261	0.000644	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ESR1—atherosclerosis	0.000255	0.000628	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—F2—atherosclerosis	0.000252	0.000621	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—atherosclerosis	0.000241	0.000594	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK3—atherosclerosis	0.000231	0.000569	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—INS—atherosclerosis	0.000228	0.000562	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL2—atherosclerosis	0.000224	0.000553	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1—atherosclerosis	0.00022	0.000544	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SERPINE1—atherosclerosis	0.000209	0.000516	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—atherosclerosis	0.000204	0.000502	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOS3—atherosclerosis	0.0002	0.000493	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK3—atherosclerosis	0.000194	0.00048	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFB1—atherosclerosis	0.000189	0.000466	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—atherosclerosis	0.000177	0.000437	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—atherosclerosis	0.000171	0.000422	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—atherosclerosis	0.000169	0.000416	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—atherosclerosis	0.00016	0.000396	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NFKB1—atherosclerosis	0.000159	0.000391	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK8—atherosclerosis	0.000156	0.000385	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—atherosclerosis	0.000155	0.000384	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—atherosclerosis	0.000144	0.000355	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—atherosclerosis	0.000143	0.000352	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—atherosclerosis	0.000142	0.000351	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK3—atherosclerosis	0.000136	0.000336	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFB1—atherosclerosis	0.000132	0.000326	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—atherosclerosis	0.000131	0.000324	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—atherosclerosis	9.96e-05	0.000246	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—atherosclerosis	9.18e-05	0.000227	CbGpPWpGaD
